Clinical Trial

A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of a novel transdermal formulation of SFG-02 following single and repeated applications in Japanese and White healthy adult participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-04.
Status change: Recruiting → Completed 2026-04-27
Trial Details
NCT Number NCT07167914
Lead Sponsor Juro Sciences Inc.
Conditions Health Participants
Enrollment 32 participants
Start Date 2025-09-09
Primary Completion 2026-04-27 (estimated)
Study Completion 2026-04-27 (estimated)
Updated on ClinicalTrials.gov 2026-04-29